Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial
Bart Jan Kullberg(Radboud University Nijmegen), George R. Thompson(Office of Infectious Diseases), Coleman Rotstein(Hamilton Health Sciences), Rodney Croos‐Dabrera(Astellas Pharma (United States)), Ploenchan Chetchotisakd(Khon Kaen University), Raoul Herbrecht(Institut de Cancérologie Strasbourg), Christine Fredericks(Astellas Pharma (United States)), Marc Engelhardt(Basilea Pharmaceutica (Switzerland)), Laura Kovanda(Astellas Pharma (Japan)), Christopher Lademacher(Astellas Pharma (United States)), Jack D. Sobel(Wayne State University), Galia Rahav(Unknown), Luis Ostrosky‐Zeichner(The University of Texas Health Science Center), Eric Van Wijngaerden(KU Leuven), José A. Vázquez(Augusta University), Claudio Viscoli(Radboud University Nijmegen), Jan J. De Waele(Ghent University Hospital), Peter G. Pappas(University of Alabama at Birmingham), Sutep Jaruratanasirikul(Prince of Songkla University)
Cited by 178
Related Papers
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k